AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
voglibose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics | 2845 | 83480-29-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PRKDC,SIK2,STK33,TEK,TGFBR1 | 29 | |||
| kinase-selectivity-class | ACVRL1,AXL,BMX,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,IGF1R,INSR,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K14,PDK1,PIK3CD,TGFBR1,ZAP70 | 25 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 20, 1994 | PMDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 121.56 | 33.46 | 46 | 1582 | 69802 | 90557017 |
| Pneumatosis intestinalis | 73.06 | 33.46 | 16 | 1612 | 3421 | 90623398 |
| Renal impairment | 69.32 | 33.46 | 35 | 1593 | 105386 | 90521433 |
| Hepatic function abnormal | 54.34 | 33.46 | 23 | 1605 | 46265 | 90580554 |
| Hypoglycaemic coma | 53.01 | 33.46 | 12 | 1616 | 2978 | 90623841 |
| Lactic acidosis | 52.43 | 33.46 | 23 | 1605 | 50440 | 90576379 |
| Diabetes mellitus inadequate control | 46.24 | 33.46 | 16 | 1612 | 18668 | 90608151 |
| Glycosylated haemoglobin increased | 45.09 | 33.46 | 15 | 1613 | 15547 | 90611272 |
| Cerebral infarction | 44.28 | 33.46 | 17 | 1611 | 26579 | 90600240 |
| Altered state of consciousness | 38.10 | 33.46 | 16 | 1612 | 31516 | 90595303 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 117.40 | 24.64 | 50 | 2467 | 31119 | 42587699 |
| Hypoglycaemia | 86.44 | 24.64 | 50 | 2467 | 59804 | 42559014 |
| Interstitial lung disease | 71.59 | 24.64 | 49 | 2468 | 78413 | 42540405 |
| Pemphigoid | 48.46 | 24.64 | 20 | 2497 | 11447 | 42607371 |
| Pneumatosis intestinalis | 45.01 | 24.64 | 15 | 2502 | 4737 | 42614081 |
| Renal impairment | 37.54 | 24.64 | 39 | 2478 | 110189 | 42508629 |
| Glycosylated haemoglobin increased | 30.48 | 24.64 | 15 | 2502 | 12909 | 42605909 |
| Hepatic function abnormal | 28.68 | 24.64 | 24 | 2493 | 51543 | 42567275 |
| Thrombotic cerebral infarction | 26.30 | 24.64 | 6 | 2511 | 463 | 42618355 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 199.78 | 26.06 | 96 | 4355 | 116008 | 110468840 |
| Cerebral infarction | 164.53 | 26.06 | 66 | 4385 | 51772 | 110533076 |
| Renal impairment | 100.37 | 26.06 | 73 | 4378 | 188372 | 110396476 |
| Pneumatosis intestinalis | 95.67 | 26.06 | 28 | 4423 | 8501 | 110576347 |
| Interstitial lung disease | 83.42 | 26.06 | 58 | 4393 | 139276 | 110445572 |
| Hepatic function abnormal | 77.64 | 26.06 | 47 | 4404 | 89248 | 110495600 |
| Glycosylated haemoglobin increased | 71.16 | 26.06 | 29 | 4422 | 23590 | 110561258 |
| Hypoglycaemic coma | 70.22 | 26.06 | 20 | 4431 | 5513 | 110579335 |
| Pemphigoid | 62.12 | 26.06 | 25 | 4426 | 19682 | 110565166 |
| Lactic acidosis | 56.36 | 26.06 | 39 | 4412 | 92772 | 110492076 |
| Diabetes mellitus inadequate control | 52.21 | 26.06 | 25 | 4426 | 29750 | 110555098 |
| Platelet count decreased | 48.87 | 26.06 | 53 | 4398 | 230390 | 110354458 |
| Altered state of consciousness | 46.65 | 26.06 | 29 | 4422 | 57597 | 110527251 |
| Decreased appetite | 45.52 | 26.06 | 74 | 4377 | 475772 | 110109076 |
| Ketoacidosis | 43.22 | 26.06 | 16 | 4435 | 10071 | 110574777 |
| Thrombotic cerebral infarction | 36.22 | 26.06 | 8 | 4443 | 786 | 110584062 |
| Diabetic ketoacidosis | 36.16 | 26.06 | 22 | 4429 | 42036 | 110542812 |
| Diabetes mellitus | 34.52 | 26.06 | 30 | 4421 | 99351 | 110485497 |
| Cerebral haemorrhage | 34.11 | 26.06 | 25 | 4426 | 64943 | 110519905 |
| Cardiac failure | 32.69 | 26.06 | 39 | 4412 | 187587 | 110397261 |
| Hyperglycaemia | 30.19 | 26.06 | 26 | 4425 | 85064 | 110499784 |
| Hyperglycaemic hyperosmolar nonketotic syndrome | 29.91 | 26.06 | 9 | 4442 | 3000 | 110581848 |
| Drug eruption | 28.97 | 26.06 | 21 | 4430 | 53638 | 110531210 |
| Dehydration | 27.38 | 26.06 | 44 | 4407 | 279467 | 110305381 |
| Fatigue | 26.64 | 26.06 | 8 | 4443 | 1215950 | 109368898 |
| Erythema multiforme | 26.11 | 26.06 | 14 | 4437 | 21083 | 110563765 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BF03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Alpha glucosidase inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D007004 | Hypoglycemic Agents |
| MeSH PA | D065089 | Glycoside Hydrolase Inhibitors |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Glucosylceramide beta-glucosidase deficiency | indication | 190794006 | DOID:1926 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Pregnancy, function | contraindication | 289908002 | |
| Peripheral nerve disease | contraindication | 302226006 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.5 | acidic |
| pKa2 | 12.5 | acidic |
| pKa3 | 8.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Lysosomal alpha-glucosidase | Enzyme | INHIBITOR | IC50 | 7.15 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Maltase-glucoamylase, intestinal | Enzyme | IC50 | 5.89 | CHEMBL | |||||
| Sucrase-isomaltase, intestinal | Enzyme | IC50 | 7.15 | CHEMBL | |||||
| Lysosomal alpha-glucosidase | Enzyme | IC50 | 6.96 | CHEMBL | |||||
| Glycogen debranching enzyme | Enzyme | IC50 | 4.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01665 | KEGG_DRUG |
| C0532578 | UMLSCUI |
| CHEBI:32300 | CHEBI |
| VOG | PDB_CHEM_ID |
| CHEMBL476960 | ChEMBL_ID |
| DB04878 | DRUGBANK_ID |
| C102817 | MESH_SUPPLEMENTAL_RECORD_UI |
| 444020 | PUBCHEM_CID |
| 6797 | INN_ID |
| S77P977AG8 | UNII |
| 010940 | NDDF |
| 1163442006 | SNOMEDCT_US |
| 1172848007 | SNOMEDCT_US |
| C054577 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None